Apellis Pharmaceuticals, Inc. (APLS)
40.87
+0.02
(+0.05%)
USD |
NASDAQ |
Apr 15, 13:31
Apellis Pharmaceuticals Research and Development Expense (Annual) : 295.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Biogen, Inc. | 1.481B |
| Eli Lilly & Co. | 13.34B |
| Agios Pharmaceuticals, Inc. | 334.36M |
| Scholar Rock Holding Corp. | 206.78M |
| BridgeBio Pharma, Inc. | 451.95M |